Comparison of SureSwab Advanced TMA Test versus MDL OneSwab Multiplex PCR
I cannot provide a direct comparison between the SureSwab Advanced TMA test and the MDL OneSwab multiplex PCR test because neither of these specific commercial products is mentioned in the provided evidence base. The evidence discusses general testing methodologies (TMA and multiplex PCR platforms) but does not contain performance data, FDA clearance information, or clinical validation studies for these two specific branded products.
What the Evidence Does Support About Testing Technologies
Transcription-Mediated Amplification (TMA) Technology
TMA-based assays demonstrate superior sensitivity for detecting Trichomonas vaginalis, Chlamydia trachomatis, and Neisseria gonorrhoeae compared to traditional methods. 1
- The APTIMA TMA platform showed 100% sensitivity and 99.8% specificity for C. trachomatis detection from rectal swabs, significantly outperforming strand displacement amplification (56.1% sensitivity). 2
- For T. vaginalis detection in women, vaginal swab TMA was significantly more sensitive than wet mount microscopy or culture. 1
- In male subjects, urethral swab TMA demonstrated significantly higher sensitivity than culture or standard PCR for T. vaginalis. 1
- TMA technology for T. vaginalis showed 96.7% sensitivity and 97.5% specificity when compared to other molecular methods. 3
Multiplex PCR Technology Performance
Multiplex PCR panels show variable performance across different pathogens, with consistently strong results for C. trachomatis but concerning limitations for M. genitalium and T. vaginalis. 4
- Four commercial multiplex real-time PCR kits all demonstrated good performance for C. trachomatis detection. 4
- The same four kits showed low positive agreement for M. genitalium (63.3–74.1%) and T. vaginalis (51.2–68.4%) compared to reference methods. 4
- Two of the four multiplex kits (Seegene and Sacace) exhibited low positive agreement for N. gonorrhoeae detection (71.2% and 63.1%, respectively). 4
- Multiplex PCR sensitivity for T. vaginalis ranged from 55.6% to 100% depending on the specific platform tested. 5
Clinical Guideline Recommendations
The Infectious Diseases Society of America and American Society for Microbiology recommend nucleic acid amplification tests (NAATs) as the preferred diagnostic method for sexually transmitted infections, with specific endorsement of simultaneous testing for C. trachomatis, N. gonorrhoeae, and T. vaginalis. 6
- NAATs have markedly higher sensitivity than microscopy (approximately 50% for microscopy versus 86–100% for NAATs). 7
- Testing simultaneously for CT, GC, and Trichomonas is optimal for detection of the most common treatable STIs in female patients. 6
- Wet-mount microscopy for T. vaginalis has only 40–70% sensitivity relative to NAAT. 6
Bacterial Vaginosis Detection Considerations
Multiplex NAAT targeting the vaginal microbiome provides greater specificity for bacterial vaginosis than detection of Gardnerella vaginalis alone. 8
- Scored Gram stain is more specific than probe hybridization, point-of-care tests, and culture that only detect G. vaginalis. 6
- Species-level identification of Gardnerella is not required for routine diagnosis of bacterial vaginosis. 8
Critical Limitations and Pitfalls
Clinicians must verify the specific FDA clearance status, validated specimen types, and published performance characteristics for any commercial test before implementation. 6
- Not all multiplex panels include the same pathogens; some inappropriately include colonizing organisms like Ureaplasma spp. and M. hominis that should not be routinely tested. 4
- Empirical treatment based on symptoms alone results in 55.2% of prescriptions being ineffective or unnecessary. 9
- Routine multiplex PCR improved T. vaginalis detection almost six-fold compared with clinician-requested testing based on symptoms. 10
What You Should Do
Contact the manufacturers of both the SureSwab Advanced and MDL OneSwab directly to obtain:
- FDA clearance documentation and specific cleared specimen types
- Published peer-reviewed validation studies comparing their platforms to reference methods
- Sensitivity and specificity data for each pathogen included in the panel
- Information on whether the panel includes inappropriate targets (e.g., Ureaplasma spp., M. hominis)
- Turnaround time and cost per test
Then compare these manufacturer-provided specifications against the performance benchmarks established in the literature: TMA platforms achieving >95% sensitivity for T. vaginalis, and multiplex PCR platforms demonstrating >90% positive agreement for all included pathogens. 3, 1, 4